What is PathoGenetix?
PathoGenetix is at the forefront of developing an automated system designed for the rapid identification of bacteria from complex samples. The company's proprietary Genome Sequence Scanning (GSS) technology offers a significant advancement by isolating and analyzing DNA directly from enriched biological samples, bypassing the need for traditional culture methods. This innovative approach yields results in approximately five hours, drastically reducing the time compared to conventional techniques. The GSS technology holds broad applicability across crucial sectors including food safety, industrial microbiology, and clinical diagnostics and research, positioning PathoGenetix as a key player in enhancing public health and safety through faster, more accurate diagnostics.
How much funding has PathoGenetix raised?
PathoGenetix has raised a total of $24.2M across 5 funding rounds:
Series A
$4.4M
Debt
$1M
Unspecified
$1.3M
Series B
$7.5M
Series C
$10M
Series A (2008): $4.4M, investors not publicly disclosed
Debt (2010): $1M, investors not publicly disclosed
Unspecified (2010): $1.3M, investors not publicly disclosed
Series B (2011): $7.5M featuring Frazier Healthcare Ventures, Excel Venture Management, and Ascension Ventures
Series C (2013): $10M backed by HealthCare Ventures, Excel Venture Management, and Ascension Ventures
Key Investors in PathoGenetix
Frazier Healthcare Ventures
Frazier Healthcare Ventures is a prominent venture capital firm specializing in the healthcare sector, known for its strategic investments in companies aiming to transform patient care and medical innovation. Their focus often includes companies in the late clinical-stage and commercialization phases.
Excel Venture Management
Excel Venture Management is an investment firm that backs innovative companies, likely focusing on technology and healthcare sectors where significant growth potential exists. Their participation suggests a belief in PathoGenetix's disruptive technology.
Ascension Ventures
Ascension Ventures is a strategic healthcare venture firm that invests on behalf of leading community health systems, focusing on companies that are transforming the healthcare industry. Their involvement indicates a strategic alignment with improving healthcare delivery and diagnostics.
What's next for PathoGenetix?
With the recent infusion of major strategic capital, PathoGenetix is poised for significant expansion and commercialization. The company's focus on accelerating the availability of its GSS system for food safety testing and outbreak investigations indicates a clear path toward market leadership. Future developments will likely involve scaling production, expanding its sales and support infrastructure, and potentially exploring new applications for its rapid identification technology in other high-stakes sectors. This strategic investment signals strong confidence in PathoGenetix's ability to disrupt existing diagnostic paradigms and address urgent needs in pathogen detection.
See full PathoGenetix company page
